Video

Dr. Chang on robot-assisted versus open radical prostatectomies

Author(s):

Urology Times staff

“The quality of life overall between the 2 approaches was very similar,” says Peter Chang, MD, PhD.

In this video Peter Chang, MD, PhD, discusses the background and findings of the Journal of Urology study, “Prospective multicenter comparison of open and robotic radical prostatectomy: The PROST-QA/RP2 consortium.” Chang is an assistant professor of surgery at Harvard Medical School and the director of the Prostate Cancer Care Center at Beth Israel Deaconess Medical Center, Boston, Massachusetts.

Related Videos
Blurred interior of hospital | Image Credit: © jakkapan - stock.adobe.com
Related Content
Prostate cancer cells, 3D illustration| © Dr_Microbe - stock.adobe.com
February 14th 2025

Real-world studies underline safety, efficacy of radium-223 in mCRPC

Benjamin P. Saylor
A total of 37 studies included real-world OS as an outcome; in these studies, median real-world OS ranged from 9 months to 23.5 months.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Blur image of hospital | Image Credit: © jakkapan - stock.adobe.com
February 14th 2025

Radium-223 re-treatment is safe in patients with mCRPC

Benjamin P. Saylor
The median number of re-injections was 6 (range, 1-12).
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland | © Dr_Microbe - stock.adobe.com
February 13th 2025

Race subgroup analysis points to clinical benefit of darolutamide in nmCRPC

Benjamin P. Saylor
In both racial cohorts, median MFS was not reached in the darolutamide group.
Conceptual image for viral ethiology of prostate cancer | © Dr_Microbe - stock.adobe.com
February 13th 2025

STOPCAP: ARPIs benefit younger patients with mHSPC

Benjamin P. Saylor
“Looking at our overall results, not surprisingly, we can show a clear benefit of ARPIs on overall survival," says David Fisher, MSc, MA.
© 2025 MJH Life Sciences

All rights reserved.